

## Pubblicazioni dal 2002 al 2014

- 1) Mariotti J, Maura F, Spina F, Roncari L, Dodero A, Farina L, **Montefusco V**, Carniti C, Sarina B, Patriarca F, Rambaldi A, Onida F, Olivieri A, Zallio F, Corradini P. Impact of Cytomegalovirus Replication and CMV serostatus on the Outcome of Patients with B-cell Lymphoma after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2014 Feb 27. pii: S1083-8791(14)00102-5PubMed PMID: 24583412.
- 2) Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, **Montefusco V**, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *J Clin Oncol.* 2014 Mar 1;32(7):634-40. PubMed PMID: 24449241.
- 3) Larocca A, **Montefusco V**, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. *Blood.* 2013 Oct 17;122(16):2799-806. PubMed PMID: 23954889.
- 4) Locatelli P, **Montefusco V**, Sini E, Restifo N, Facchini R, Torresani M. ICT and mobile health to improve clinical process delivery. a research project for therapy management process innovation. *Stud Health Technol Inform.* 2013;192:1105. PubMed PMID: 23920879.
- 5) Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, **Montefusco V**, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. *Blood.* 2013 Aug 22;122(8):1376-83. PubMed PMID: 23775712.
- 6) Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, Dodero A, **Montefusco V**, Carlo-Stella C, Corradini P. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. *Leuk Lymphoma.* 2014 Feb;55(2):331-6. PubMed PMID: 23656194.
- 7) Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, **Montefusco V**, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, Corradini P, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. *Biol Blood Marrow Transplant.* 2013 Jun;19(6):940-8. PubMed PMID: 23538113.
- 8) Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, **Montefusco V**, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica.* 2013 Jun;98(6):980-7. PubMed PMID: 23445873; PubMed Central PMCID: PMC3669456.
- 9) **Montefusco V**, Spina F, Patriarca F, Offidani M, Bruno B, Montanari M, Mussetti A, Sperotto A, Scortechni I, Dodero A, Fanin R, Valagussa P, Corradini P. Bortezomib plus dexamethasone

followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Mar;19(3):424-8. PubMed PMID: 23142330.

- 10) Mussetti A, Dalto S, **Montefusco V**. Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma. 2013 Apr;54(4):864-6. PubMed PMID: 22880953.
- 11) Corso A, Galli M, Mangiacavalli S, Rossini F, Nozza A, Pascutto C, **Montefusco V**, Baldini L, Cafro AM, Crippa C, Cazzola M, Corradini P. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. Am J Hematol. 2012 Feb;87(2):150-4. PubMed PMID: 22189759.
- 12) Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, **Montefusco V**, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011 Nov 24;118(22):5759-66. PubMed PMID: 21951682.
- 13) Spina F, **Montefusco V**, Crippa C, Citro A, Sammassimo S, Olivero B, Gentili S, Galli M, Guglielmelli T, Rossi D, Falcone AP, Grasso M, Patriarca F, De Muro M, Corradini P. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leuk Lymphoma. 2011 Jul;52(7):1262-70. PubMed PMID: 21534872.
- 14) Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, **Montefusco V**, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011 Mar 10;29(8):986-93. PubMed PMID: 21282540.
- 15) Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, **Montefusco V**, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010 Dec 1;28(34):5101-9. PubMed PMID: 20940200.
- 16) Palumbo A, Gay F, Falco P, Crippa C, **Montefusco V**, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010 Feb 10;28(5):800-7. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314. PubMed PMID: 20048187.
- 17) Pezzoli G, Tesei S, Canesi M, Sacilotto G, **Vittorio M**, Mizuno Y, Mochizuki H, Antonini A. The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. Clin Neurol Neurosurg. 2010 Jan;112(1):65-7. PubMed PMID: 19765889.

- 18) Coluccia P, **Montefusco V**, Tunesi S, Avella M, Bompadre A, Longoni P, Milanesi M, De Carli A, Ravagnani F. Peripheral blood stem cell collection in multiple myeloma: a retrospective analysis of 6 years leukapheresis activity in 109 patients treated at the Istituto Nazionale dei Tumori of Milan. *J Clin Apher.* 2009;24(4):134-40. PubMed PMID: 19591198.
- 19) **Montefusco V**, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *Leuk Lymphoma.* 2008 Nov;49(11):2156-62. PubMed PMID: 19021059.
- 20) Corradini P, **Montefusco V**. Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients? *Nat Clin Pract Oncol.* 2008 May;5(5):254-5. PubMed PMID: 18349855.
- 21) Giaccone L, Sorasio R, Patriarca F, Mattei D, **Montefusco V**, Peccatori J, Carnevale-Schianca F, Petrucci MT, Milone G, Guidi S, Rotta M, Fanin R, Corradini P, Boccadoro M, Bruno B. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. *Biol Blood Marrow Transplant.* 2007 Apr;13(4):497-9. PubMed PMID: 17382258.
- 22) Bruno B, Sorasio R, Patriarca F, **Montefusco V**, Guidi S, Busca A, Scimé R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo. Unrelated donor hematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. *Eur J Haematol.* 2007 Apr;78(4):330-7. Epub 2007 Feb 27. PubMed PMID: 17331132.
- 23) Bruno B, Patriarca F, Sorasio R, Mattei D, **Montefusco V**, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P; Gruppo Italiano Trapianti di Midollo. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. *Haematologica.* 2006 Jun;91(6):837-9. PubMed PMID: 16769588.
- 24) van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, **Montefusco V**, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. *Blood.* 2006 Apr 15;107(8):3415-6. PubMed PMID: 16597603.
- 25) Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, **Montefusco V**, Farina L, Milanesi M, Longoni P, Carlo-Stella C, Corradini P. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. *Exp Hematol.* 2005 Aug;33(8):920-7. PubMed PMID: 16038785.
- 26) Vacca A, Scavelli C, **Montefusco V**, Di Pietro G, Neri A, Mattioli M, Bicciato S, Nico B, Ribatti D, Dammacco F, Corradini P. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. *J Clin Oncol.* 2005 Aug 10;23(23):5334-46. Epub 2005 Jun 6. PubMed PMID: 15939924.
- 27) Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, **Montefusco V**, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in

patients with multiple myeloma. *Blood*. 2003 Sep 1;102(5):1927-9. Epub 2003 May 8. PubMed PMID: 12738666.

28) **Montefusco V.** Donor lymphocyte infusions as primary therapy for neoplasms. *Blood*. 2003 Jan 1;101(1):373; author reply 373-4. PubMed PMID: 12485941.

29) Buonamici S, Ottaviani E, Testoni N, **Montefusco V**, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. *Blood*. 2002 Jan 15;99(2):443-9. PubMed PMID: 11781223.